Anxiety — Clinical Documentation Guide (2026)

🔍 Definition

Anxiety disorders are a broad group of mental health conditions characterized by excessive, persistent fear or worry that is disproportionate to the actual threat and causes clinically significant distress or functional impairment. Under FY2026 ICD-10-CM, anxiety disorders are classified primarily within the F40–F48 block (“Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders”). They encompass:

• Phobic anxiety disorders (F40.x) — fear and avoidance triggered by specific external objects or situations, including agoraphobia, social anxiety disorder (SAD), and specific phobias.
• Other anxiety disorders (F41.x) — generalized anxiety disorder (GAD), panic disorder, and mixed anxiety-depressive disorder.
• Obsessive-compulsive disorder (F42.x) — recurrent obsessions and/or compulsions; in DSM-5 and ICD-10-CM FY2026 updates, F42 has expanded subcategories reflecting OCD spectrum.
• Stress/trauma-related disorders (F43.x) — acute stress reaction, PTSD (acute and chronic), and adjustment disorders.
• Childhood separation anxiety (F93.0) — developmentally inappropriate, excessive fear of separation from attachment figures.
• Substance- or medication-induced anxiety (F1x.180) and anxiety due to another medical condition (F06.4).

Anxiety disorders are the most prevalent mental health conditions in the United States, affecting an estimated 31% of U.S. adults at some point in their lives. Accurate code selection hinges on identifying the specific disorder type, chronicity, and etiology — all of which carry significant coding, HCC risk-adjustment, and reimbursement implications.

🗂️ Alternative Terminology

Clinicians and patients use a wide range of lay and clinical terms that map to ICD-10-CM anxiety categories. Coders must recognize these to link documentation to the correct code.

🩺 Signs & Symptoms

Clinical manifestations vary by disorder subtype but share a core cluster of emotional, cognitive, physical, and behavioral features. Documentation of specific symptoms supports diagnosis specificity and functional impairment coding.

Psychological / Cognitive Symptoms

• Excessive, uncontrollable worry (hallmark of GAD)
• Intrusive, recurrent thoughts or obsessions (OCD, PTSD)
• Fear of losing control, dying, or going crazy (panic disorder)
• Hypervigilance, exaggerated startle response (PTSD, acute stress)
• Anticipatory anxiety; avoidance cognitions
• Derealization or depersonalization during panic episodes
• Flashbacks, nightmares, re-experiencing (PTSD)

Physical / Somatic Symptoms

• Palpitations, tachycardia, chest tightness or pain
• Shortness of breath, choking sensation, smothering feeling
• Diaphoresis, trembling, shaking
• Nausea, GI distress, diarrhea
• Dizziness, lightheadedness, paresthesias
• Muscle tension, headache, fatigue
• Insomnia, sleep disturbances
• Hot flashes or chills

Behavioral Symptoms

• Avoidance of feared objects, situations, or places
• Compulsive rituals (hand-washing, checking, counting — OCD)
• Social withdrawal, refusal to attend school or work
• Substance use as self-medication
• Reassurance-seeking; frequent medical visits (health anxiety)
• Functional impairment in occupational, social, or academic domains

🧭 Differential Diagnosis

Distinguishing anxiety disorders from medical conditions with overlapping symptoms and from each other is essential for accurate code assignment. The table below guides coders and CDI specialists in recognizing documentation that points toward or away from anxiety diagnoses.

📋 Clinical Indicators for Coders/CDI

The following documentation elements support specific anxiety disorder codes and trigger CDI queries when absent or ambiguous. Per FY2026 ICD-10-CM Official Guidelines, code selection must be based on provider documentation — coders may not infer specificity without physician confirmation.

🦴 Anatomy & Pathophysiology

Understanding the neurobiological basis of anxiety disorders informs documentation of severity, treatment rationale, and comorbid conditions — all relevant to coding and CDI.

Neural Circuitry

Anxiety disorders involve dysregulation of the fear circuit, centered on the amygdala, which processes threat signals and activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system. The prefrontal cortex (PFC), normally providing top-down inhibition of amygdala activity, shows reduced regulatory function in GAD and PTSD, resulting in sustained hyperactivation of fear responses. The hippocampus plays a role in contextual fear conditioning and memory consolidation — hippocampal atrophy is well-documented in chronic PTSD.

Neurotransmitter Systems

• Serotonin (5-HT): Dysregulation implicated across most anxiety disorders; basis for SSRI/SNRI efficacy.
• GABA: The primary inhibitory neurotransmitter; benzodiazepines augment GABA-A receptor function to produce anxiolytic effects.
• Norepinephrine: Elevated in PTSD and panic disorder; explains cardiovascular symptoms and arousal; SNRIs and beta-blockers target this pathway.
• Glutamate: Excessive NMDA-mediated excitatory transmission; ketamine and other glutamatergic agents under investigation.
• Corticotropin-releasing factor (CRF): HPA axis hyperactivation drives cortisol elevation; chronic stress response in GAD and PTSD.

Genetic and Environmental Factors

Heritability estimates range from 30–67% depending on disorder. Environmental factors — childhood adversity, trauma exposure, chronic stress — interact with genetic predisposition. The APA and DSM-5 recognize the biopsychosocial model as the framework for understanding anxiety etiology.

Relevance to Coding

Physiological manifestations of anxiety (tachycardia, hypertension, insomnia, GI distress) frequently generate additional codes. Coders should capture comorbid conditions documented and managed in the same encounter — for example, insomnia (G47.00) or irritable bowel syndrome (K58.x) when documented as related to anxiety.

💊 Medication Impact / Treatment

Pharmacological treatment of anxiety disorders affects coding in several ways: adverse effects and interactions generate additional codes, substance-induced anxiety requires evaluation of medication lists, and treatment response documentation supports chronic condition coding.

First-Line Pharmacotherapy

• SSRIs (sertraline, escitalopram, paroxetine, fluoxetine) — first-line for GAD, panic disorder, SAD, OCD, PTSD. Onset 2–6 weeks. Coding alert: document if therapeutic or if adverse effect (e.g., increased anxiety at initiation — T43.225A).
• SNRIs (venlafaxine, duloxetine) — FDA-approved for GAD and social anxiety. Blood pressure monitoring required; document hypertension separately if present.
• Buspirone — Non-benzodiazepine anxiolytic approved for GAD; no dependence risk; may cause dizziness (adverse effect coding may apply).
• Benzodiazepines (lorazepam, clonazepam, alprazolam) — Short-term use for acute anxiety and panic; significant misuse/dependence risk. If dependence develops, F13.2x applies. Withdrawal may cause anxiety — code F13.232 if relevant.
• Pregabalin / Gabapentin — Off-label anxiolytics; pregabalin is guideline-supported for GAD in European guidelines (WFSBP).

OCD-Specific Pharmacotherapy

• Higher-dose SSRIs required (e.g., fluvoxamine, clomipramine); clomipramine has cardiac monitoring needs (QTc prolongation — I49.x if documented).

PTSD Pharmacotherapy

• Sertraline and paroxetine are FDA-approved for PTSD. Prazosin for nightmares (alpha-1 blocker; monitor for orthostatic hypotension — I95.1 if documented).

Coding Implications of Medications

• If benzodiazepine dependence is documented, code F13.20–F13.29 in addition to anxiety disorder.
• Medication-induced anxiety (e.g., stimulants, steroids, thyroid hormone) → F06.4 or substance/medication-induced category.
• When documenting medication management for anxiety, ensure the specific anxiety disorder is named — this supports E/M medical decision-making complexity and HCC capture.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines from the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (Section I.C.5 — Mental, Behavioral, and Neurodevelopmental Disorders) govern anxiety disorder coding:

General Mental Health Coding Rules (Section I.C.5)

• Code the specific mental health disorder when documented by the treating clinician.
• When a mental health disorder is documented as “rule out,” code it as if confirmed for inpatient encounters; do not code unconfirmed diagnoses for outpatient/ED encounters (code signs and symptoms instead).
• Comorbid mental health conditions (e.g., GAD + MDD) should each be coded when documented and managed in the same encounter.

Anxiety Disorder-Specific Guidance

• Panic disorder (F41.0): Characterized by recurrent unexpected panic attacks. Do not confuse with isolated panic attacks in the setting of phobias (F40.01) or without a disorder-level diagnosis.
• GAD (F41.1): Requires provider documentation of generalized anxiety disorder — duration, functional impact, and symptom cluster support this code. When comorbid with depression, code both F41.1 and the appropriate F32.x/F33.x code.
• F41.3 (Other mixed anxiety and depressive disorder): Use when anxiety and depression are both present but neither predominates; distinct from coding GAD + MDD separately.
• OCD (F42.x): FY2026 expands F42 subcategories. F42.2 (mixed obsessional thoughts and acts), F42.3 (hoarding disorder), F42.4 (excoriation disorder), F42.8 (other OCD and related disorders), F42.9 (OCD unspecified). Assign the most specific subcategory supported by documentation.
• PTSD (F43.10–F43.12): Code to acute (F43.11, duration <3 months) or chronic (F43.12, duration ≥3 months). Use F43.10 (unspecified) only when duration is not documented.
• Adjustment disorders (F43.2x): Require identification of the stressor and predominant presentation. F43.22 (anxiety), F43.23 (mixed anxiety and depression), F43.24 (disturbance of conduct), F43.25 (mixed disturbance of emotions/conduct), F43.29 (other).
• Substance-induced anxiety: Use the appropriate substance-specific code (e.g., F10.180 for alcohol-induced anxiety, F14.180 for cocaine-induced). Add the anxiety disorder code only if the clinician documents a comorbid primary anxiety disorder.
• F06.4 (Anxiety disorder due to known physiological condition): Code the underlying medical condition first (e.g., E05.00 for hypothyroidism), followed by F06.4. Use an additional code for associated anxiety type if documented.
• F93.0 (Separation anxiety disorder of childhood): Applicable when criteria are met developmentally; in adults presenting with separation anxiety, consider F41.8 (other specified anxiety) if provider confirms adult separation anxiety disorder.

Principal Diagnosis Selection

For inpatient encounters, the anxiety disorder that is chiefly responsible for admission after study should be sequenced first. If the patient presents with a panic attack that is determined to be a manifestation of cardiac disease, the cardiac code is principal. For outpatient encounters, code the condition to the highest degree of certainty — for anxiety, this means the specific disorder when documented.

🔢 ICD-10-CM Code Set (FY2026)

All codes below are valid for FY2026 (effective October 1, 2025) per the CDC/NCHS ICD-10-CM tabular list.

🔎 Indexing

The ICD-10-CM Alphabetic Index provides the following primary lead terms and subterms for anxiety-related conditions. Always verify in the Tabular List before assigning.

🏥 CPT (2026)

The following CY2026 CPT codes apply to anxiety disorder evaluation and management. Verify payer-specific coverage policies before billing.

🧾 HCPCS (2026)

The following CY2026 HCPCS Level II codes apply primarily in behavioral health settings, community-based programs, and Medicaid-covered services for anxiety disorders.

📚 AHA Coding Clinic (Recent Guidance)

The AHA Coding Clinic for ICD-10-CM/PCS has addressed anxiety disorder coding in several recent advisories. The following summarizes key guidance applicable to FY2026:

Note: Specific Coding Clinic volume/issue citations are not publicly available in full text; subscribers should verify guidance in the AHA Central Office portal. Guidance above reflects published advisories through early 2026.

💰 HCC / Risk Adjustment (v28)

Under the CMS-HCC Model v28 (phased in 2024–2026 and fully implemented for payment year 2026), anxiety disorder codes have distinct hierarchical and RAF weight implications.

✍️ CDI Query Templates

All query templates below are compliant with AHIMA/ACDIS 2019 Guidelines for CDI Queries: non-leading, multiple-choice options, clinical evidence-based, and include a “clinically undetermined” option. Queries should be sent to the treating provider; do not alter diagnosis without provider response.

🧑‍⚕️ Treatments (Clinical)

Treatment documentation supports coding of the specific disorder, medical necessity, and E/M complexity. The following evidence-based treatments are endorsed by the American Psychiatric Association (APA) and NICE Guidelines.

Psychotherapy

• Cognitive Behavioral Therapy (CBT) — Gold standard for GAD, panic disorder, OCD, SAD, specific phobias, and PTSD. Includes exposure-based techniques, cognitive restructuring, and response prevention (ERP for OCD).
• Exposure and Response Prevention (ERP) — Specific protocol for OCD; first-line alongside SSRI.
• Prolonged Exposure (PE) and EMDR — Evidence-based for PTSD; EMDR (Eye Movement Desensitization and Reprocessing) is VA/DoD guideline-endorsed.
• Acceptance and Commitment Therapy (ACT) — Third-wave CBT; emerging evidence for GAD and OCD.
• Dialectical Behavior Therapy (DBT) — For emotion dysregulation comorbid with anxiety; especially PTSD in complex trauma.

Pharmacotherapy (see also Section 7)

• SSRIs / SNRIs: First-line across most anxiety disorders.
• Benzodiazepines: Short-term adjunct; monitor for dependence (F13.2x if develops).
• Buspirone: Adjunct for GAD; non-sedating.
• Prazosin: Nightmares/hyperarousal in PTSD.
• Beta-blockers (propranolol): Performance anxiety (situational SAD); not for disorder-level treatment.
• Augmentation: Atypical antipsychotics (quetiapine, aripiprazole) in treatment-resistant GAD.

Integrated and Collaborative Care

• Collaborative Care Model (CoCM): PCP + behavioral health care manager + consulting psychiatrist. Effective for GAD and panic in primary care settings. Billed as 99492–99494 or G2214.
• Stepped Care: Begins with brief interventions (psychoeducation, self-help), escalates to CBT, then combined treatment for refractory cases.

Complementary and Lifestyle

• Regular aerobic exercise — evidence for GAD symptom reduction (APA guidelines).
• Mindfulness-Based Stress Reduction (MBSR) — Adjunctive benefit in GAD.
• Sleep hygiene — Critical for insomnia comorbid with anxiety; document G47.00 if diagnosed.

🎓 Patient Education / Summary

The following points support patient-facing communication and documentation of patient education (which may support medical necessity and E/M complexity). Coders and CDI specialists should confirm that patient education relevant to the specific anxiety disorder is documented in the encounter note.

Key Patient Education Points

• Anxiety disorders are medical conditions — not character flaws or weaknesses. They result from brain chemistry, genetics, and life experiences.
• Treatment works — The majority of people with anxiety disorders improve significantly with CBT, medication, or both. Encourage engagement with treatment plans.
• GAD-7 self-monitoring — Patients can track symptom severity with the validated GAD-7 questionnaire between visits; scores ≥ 10 warrant clinical discussion.
• Panic disorder — Panic attacks, while frightening, are not medically dangerous. Understanding the physiology (fight-or-flight response) reduces fear of the attacks themselves.
• Avoidance worsens anxiety — Avoiding feared situations reinforces anxiety long-term; gradual exposure is a core treatment strategy.
• Medication timeline — SSRIs/SNRIs require 2–6 weeks to take effect; premature discontinuation is a common cause of treatment failure.
• Substance use and anxiety — Alcohol and cannabis may temporarily reduce anxiety but worsen it over time; discuss with provider.
• Crisis resources — For acute distress or safety concerns: 988 Suicide and Crisis Lifeline (call or text 988); Crisis Text Line (text HOME to 741741).

Documentation Checklist for Coders

Before finalizing anxiety disorder coding, verify the record contains:

• ☐ Specific anxiety disorder type named by provider (not just “anxiety”)
• ☐ Duration / chronicity noted (especially for GAD ≥6 months; PTSD acute/chronic)
• ☐ Functional impairment documented (occupational, social, academic domains)
• ☐ Comorbid depression coded separately if present and managed
• ☐ GAD-7 or other validated screening score linked to diagnosis
• ☐ Substance use relationship clarified (induced vs. primary)
• ☐ Medical condition etiology ruled out or coded (F06.4 if applicable)
• ☐ HCC-mapped codes (F41.1, F40.1x) documented in assessment/plan (not only problem list)
• ☐ Annual reaffirmation of chronic anxiety diagnoses for MA risk adjustment

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)